Small Molecule Drug Development Services

Small molecule drugs for brain tumors are therapeutic agents that can penetrate the blood-brain barrier to target specific molecular pathways involved in tumor growth, survival, and metastasis. Alfa Cytology provides comprehensive development services for small molecule drugs targeting brain tumors, offering expertise in drug discovery, optimization, preclinical testing, and regulatory support to advance these promising therapies.

Introduction to Small Molecule Drugs for Brain Tumors

Small molecule drugs can reach intracellular or extracellular targets of immune cells involved in specific immune pathways, enhance antitumor immunity, or reduce immunosuppression. Brain tumor small molecule drugs also have potential complementary or synergistic effects with existing immunotherapies. Compared to therapeutic antibodies, small molecule drugs have greater penetration into the tissue and tumor microenvironment (TME). It can cross physiological barriers such as the blood-brain barrier, providing new options for the treatment of brain tumors and brain metastases.

Fig 1. A model of the mechanism by which GA-amide inhibited cell invasion and induced cell apoptosis in glioma. (QU J, et al., 2023)

Small Molecule Drug Development for Brain Tumors

Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Alfa Cytology possesses significant strengths in providing development services for small molecule drugs targeting brain tumors, supported by a dedicated team of experts in oncology, pharmacology, and medicinal chemistry. With advanced laboratories and a proven track record in drug discovery and preclinical development, Alfa Cytology is well-equipped to drive the advancement of novel therapeutics in this field.

Workflow of Small Molecule Drug Development

Drug Target Identification

Identifying molecular targets associated with the disease, usually by studying the disease mechanisms to determine potential drug action targets. These targets can be proteins, enzymes, receptors, nucleic acids, etc.

Drug Design and Synthesis

Designing small-molecule compounds with potential activity based on the structural and functional information of the target.

• AI-based Drug Design
• Drug Screening

• Hit-to-Lead
• Lead Optimization

In Vitro Pharmacodynamic Evaluation

Assessing the activity of small-molecule compounds at the cellular level, including experiments like cell proliferation inhibition assays, apoptosis assays, cell cycle analysis, and more.

In Vivo Pharmacodynamic Evaluation

Evaluating the therapeutic effects of small-molecule compounds in animal models, including monitoring indicators such as tumor volume, animal survival time, histopathological changes, etc.

Modeling Services for Brain Tumors

To support new drug development and preclinical testing, Alfa Cytology offers a diverse range of in vivo and in vitro models for small-molecule studies targeting brain tumors.

In Vitro Models

• Cell Line Development for Brain Tumors
• Organoids and Organ Chip for Brain Tumors
• Blood Brain Barrier Models Development for Brain Tumors

In Vivo Models

• Xenograft Brain Tumor Models
• Syngeneic Brain Tumor Models
• Humanized Brain Tumor Models
• Virus-induced Brain Tumor Models
• Transgenic Brain Tumor Models
• Metastatic Brain Tumor Models

Alfa Cytology provides comprehensive, one-stop radiotherapy solutions for brain tumors, offering advanced treatments such as radionuclide-labeled molecules and radioimmunotherapy to ensure precise and effective care. If you have any related needs, please feel free to contact us for professional consultation and customized solutions.

Reference

1. QU J, QIU B, ZHANG Y, et al. The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling [J]. Signal transduction and targeted therapy, 2023, 8(1): 424.